UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000037855
Receipt number R000043158
Scientific Title Evaluation of glycation index, beauty index, glucose metabolism and liver function improvement from ingestion of test food.
Date of disclosure of the study information 2019/08/30
Last modified on 2022/09/20 22:48:13

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Evaluation of glycation index, beauty index, glucose metabolism and liver function improvement from ingestion of test food.

Acronym

Evaluation of glycation index, beauty index, glucose metabolism and liver function improvement from ingestion of test food.

Scientific Title

Evaluation of glycation index, beauty index, glucose metabolism and liver function improvement from ingestion of test food.

Scientific Title:Acronym

Evaluation of glycation index, beauty index, glucose metabolism and liver function improvement from ingestion of test food.

Region

Japan


Condition

Condition

Healthy adult

Classification by specialty

Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the anti-glycation effect, beauty effect, glucose metabolism from ingestion of test food.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2


Developmental phase

Not applicable


Assessment

Primary outcomes

Evaluate skin AGEs accumulation, internal body AGEs, skin wrinkles, HOMA-IR, AST and ALT when taking the study food continuously for 12 weeks.

Key secondary outcomes

Evaluate other cosmetic indicators, glucose metabolism and liver function items when the study food is continually consumed for 12 weeks.


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Prevention

Type of intervention

Food

Interventions/Control_1

Ingestion of capsules including mixed plant extract once a day for 12 weeks.

Interventions/Control_2

Ingestion of capsules not including mixed plant extract once a day for 12 weeks.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

40 years-old <=

Age-upper limit

65 years-old >

Gender

Female

Key inclusion criteria

(1) Female ages 40 or more and less than 65 years old
(2) Subjects with a lot of skin AGEs accumulation

Key exclusion criteria

(1)smoking subjects
(2)subjects who have a habit of drinking more than 4 times a week
(3)less than five hours in mean sleep
(4)routinely taking foods or medicines which may affect skin or blood glucose
(5)BMI more than 30
(6)treatment or a history of serious disease or affecting a secretion of sex hormones
(7)diseases which affect this study
(8)expected to be developed the allergy symptoms on skin
(9)donated > 200 mL of blood within 1 month or > 400 mL within 3 months prior to the study
(10)eat or drink too much during this trial, or who have a habit of eating out
(11)treated cosmetic care
(12)treated cosmetic care except for measuring sites, or hormonal therapy for one year
(13)a facial, a wash-rag, lost hair on measuring sites for one month ago, or plans these actions
(14)no habit of preventing sunburn
(15)plan to have ultraviolet exposure within a month before the screening test
(16)wash the body providing strong skin irritation
(17)the skin chronic disease including atopic dermatitis
(18)subjects who have the wound or inflammatory disease affecting the measuring skin
(19)trouble by rough skin around a menstruates
(20)subjects who work for anti-glycation foods related companies, or subjects who have family members working for such companies
(21)employed on a pre-dawn shift or on night duty more than 2 times
(22)planned to go overseas
(23)possibilities for emerging allergy related to the study
(24)judged as unsuitable for the study based on the results of clinical and physical examination on screening test
(25)participated in other clinical study within the last one month prior to the current study or are planned to participate in other clinical study after informed consent for the current study
(26)planned to become pregnant after informed consent for the current study or are pregnant or lactating
(27)judged as unsuitable for the study based on the results of lifestyle questionnaire
(28)judged as unsuitable for the study by the investigator for other reasons

Target sample size

40


Research contact person

Name of lead principal investigator

1st name Sumio
Middle name
Last name Kondo

Organization

Medical Corporation Kensho-kai, Fukushima Healthcare Center

Division name

Internal Medicine, Department of Neurosurgery

Zip code

553-0004

Address

2-12-16, Tamagawa, Fukushima-ku, Osaka-shi, Osaka

TEL

06-6441-6848

Email

ko293434@ares.eonet.ne.jp


Public contact

Name of contact person

1st name Naoki
Middle name
Last name Matsuo

Organization

Karada Lab, Inc.

Division name

No division

Zip code

602-0008

Address

Yousuien-nai, 59 Gansuin-cho, Kamigyo-ku, Kyoto, JAPAN

TEL

070-2440-3772

Homepage URL


Email

matsuo.hv@arkray.co.jp


Sponsor or person

Institute

TTC Co., Ltd

Institute

Department

Personal name



Funding Source

Organization

ARKRAY, Inc.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Aisei Hospital Ueno Clinic Research Ethics Committee

Address

2-18-6, Higashiueno, Taitou-ku, Tokyo

Tel

03-6455-0880

Email

t.saito@ttc-smo.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2019 Year 08 Month 30 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2019 Year 07 Month 25 Day

Date of IRB

2019 Year 07 Month 25 Day

Anticipated trial start date

2019 Year 09 Month 04 Day

Last follow-up date

2019 Year 12 Month 18 Day

Date of closure to data entry

2020 Year 01 Month 17 Day

Date trial data considered complete

2020 Year 01 Month 24 Day

Date analysis concluded

2020 Year 02 Month 25 Day


Other

Other related information



Management information

Registered date

2019 Year 08 Month 30 Day

Last modified on

2022 Year 09 Month 20 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000043158


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name